Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins...

Transgenomic and Power3 Medical Report Identification of Abnormal Serum
Proteins in Parkinson's Disease
On-line Publication of Biomarker Panel that Forms Basis for NuroPro(R)PD
Diagnostic Test

OMAHA, Neb. and HOUSTON, Sept. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin
Board: PWRM) today announced the advance on-line publication of a clinical
research paper entitled "Abnormal Serum Concentrations of Proteins in
Parkinson's Disease" in the scientific journal Biochemical and Biophysical
Research Communications. The study demonstrates the usefulness of a protein
biomarker panel to distinguish Parkinson's disease (PD) patients from
age-matched normal controls independent of the severity of symptoms, using
clinical blood serum samples.

The analytic technology forms the basis for the NuroPro(R)PD test for PD being
commercialized by Transgenomic as per a licensing/collaboration agreement with
Power3 Medical signed in early 2009. The publication of the peer-reviewed
article is a significant validation milestone in the ongoing clinical
development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel
electrophoresis to identify protein biomarkers for diagnosing PD using serum
from routinely collected blood samples. 57 protein biomarkers, which had been
discovered using retrospective blood serum samples from various
neurodegenerative diseases, were then applied specifically to PD in a
prospective clinical investigation using freshly collected blood serum from PD
patients and age-matched normal controls. A multi-variate statistical method,
stepwise linear discriminant analysis, selected a combination of 21 of the
biomarkers as optimal to distinguish PD patients from controls. When applied
to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD
correctly classified) and specificity of 92.9% (28 of 30 controls correctly
classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe
symptoms were correctly classified, as were all 6 PD samples from an
independent site.

"We are enthusiastic about the acceptance of our paper in this established
peer-reviewed scientific journal. It represents independent external
validation of the clinical data, and so increases the confidence that we have
in NuroProPD to be a meaningful tool for the diagnosis of Parkinson's disease,
especially early in its course," said Craig Tuttle, CEO of Transgenomic. "We
are completing the clinical validation of the assay in our CLIA-certified
molecular testing laboratory and will be launching the assay in the very near
future."

"In the U.S., there are an estimated 1.5 million individuals with Parkinson's
disease. Unfortunately, by the time patients are given a probable diagnosis,
many have already suffered substantial and irreparable brain damage, rendering
treatment less effective," said Dr. Ira Goldknopf, President and CSO of Power3
Medical and lead author on the paper. "The fact that these results were
obtained using fresh blood serum, in the same way that the test will be
performed in a clinical diagnostic setting, provides further support for their
robustness and their commercial value."

Clinical investigators in the study were Dr. Katerina Markopoulou of the
University of Thessaly, Greece, Drs. Marwan Sabbagh and Holly Shill of Banner
Sun Health Research Institute, Sun City, Arizona, and Dr. Stanley Appel of the
Texas Methodist Health System, Houston.

About Transgenomic, Inc.
Transgenomic, Inc. (OTC BB: TBIO.OB, www.transgenomic.com ) is a global
biotechnology company specializing in high sensitivity genetic variation and
mutation analysis, providing products and services in DNA mutation detection
and discovery for clinical research, clinical molecular diagnostics and
pharmacogenomics analyses. Its product offerings include the WAVE(R) Systems
and associated consumables specifically designed for use in genetic variation
detection and single- and double-strand DNA/RNA analysis and purification.
With broad applicability to genetic research, over 1,450 systems have been
shipped to customers in more than 30 countries. The SURVEYOR(R) Mutation
Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for
high sensitivity detection of mutations in DNA. In addition, HANABI automated
chromosome harvesting systems improve laboratory productivity with consistent
quality compared to manual methods for cytogenetic analyses. Service offerings
include the Transgenomic Molecular Laboratory, which provides reference
laboratory services specializing in molecular diagnostics including
Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and
Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for
pharmacogenomic, translational research and clinical trials.

About Power3 Medical Products, Inc.
Power3 Medical Products, Inc. (OTCBB: PWRM, www.power3medical.com ) is a
leading bio-medical company engaged in the commercialization of
neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of
diseases through the development of diagnostic tests and drug targets. Power3
Medical operates a state-of-the-art CLIA certified laboratory in The Woodlands
(Houston), Texas.

Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic
products and services markets. The known risks, uncertainties and other
factors affecting these forward-looking statements are described from time to
time in reports to the Securities and Exchange Commission. Any change in such
factors, risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 with respect to all statements contained in this press
release.

SOURCE Transgenomic, Inc.; Power3 Medical Products, Inc.

Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, investorrelations@transgenomic.com